AstraZeneca PLC
LSE:AZN

Watchlist Manager
AstraZeneca PLC Logo
AstraZeneca PLC
LSE:AZN
Watchlist
Price: 13 592 GBX 0.58% Market Closed
Market Cap: 210.8B GBX

Profitability Summary

AstraZeneca PLC's profitability score is hidden . We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
AstraZeneca PLC

Revenue
58.1B USD
Cost of Revenue
-10.5B USD
Gross Profit
47.6B USD
Operating Expenses
-33.5B USD
Operating Income
14.2B USD
Other Expenses
-4.8B USD
Net Income
9.4B USD

Margins Comparison
AstraZeneca PLC Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP
82%
24%
16%
US
Eli Lilly and Co
NYSE:LLY
955.6B USD
83%
44%
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
3%
-4%
US
Johnson & Johnson
NYSE:JNJ
485.9B USD
68%
27%
27%
CH
Roche Holding AG
SIX:ROG
247.5B CHF
74%
34%
15%
CH
Novartis AG
SIX:NOVN
205.5B CHF
76%
33%
26%
US
Merck & Co Inc
NYSE:MRK
248B USD
79%
38%
30%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
82%
42%
33%
IE
Endo International PLC
LSE:0Y5F
202.5B USD
68%
11%
-126%
US
Pfizer Inc
NYSE:PFE
148B USD
75%
29%
16%
FR
Sanofi SA
PAR:SAN
103.5B EUR
72%
24%
21%
No Stocks Found

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
AstraZeneca PLC Competitors

Country Company Market Cap ROE ROA ROCE ROIC
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP
22%
9%
18%
15%
US
Eli Lilly and Co
NYSE:LLY
955.6B USD
97%
19%
42%
25%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
US
Johnson & Johnson
NYSE:JNJ
485.9B USD
33%
13%
18%
13%
CH
Roche Holding AG
SIX:ROG
247.5B CHF
33%
10%
31%
18%
CH
Novartis AG
SIX:NOVN
205.5B CHF
33%
14%
25%
18%
US
Merck & Co Inc
NYSE:MRK
248B USD
40%
15%
26%
21%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
71%
23%
57%
28%
IE
Endo International PLC
LSE:0Y5F
202.5B USD
70%
-51%
5%
6%
US
Pfizer Inc
NYSE:PFE
148B USD
11%
5%
11%
10%
FR
Sanofi SA
PAR:SAN
103.5B EUR
19%
11%
16%
12%
No Stocks Found

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less